US health agency announces two Medicare pilot programs on drug pricing

The Centers for Medicare & Medicaid Services unveiled two pilot programs — GLOBE (Medicare Part B) and GUARD (Medicare Part D) — that will benchmark certain U.S. drug prices to prices in economically comparable countries and require manufacturer rebates where U.S. prices exceed those international levels. GLOBE, covering Part B medicines including cancer, autoimmune, eye and hormonal treatments, is set to launch Oct. 1 next year through 2031; GUARD will run Jan. 1, 2027–Dec. 31, 2031 for selected Part D outpatient drugs. The measures are designed to lower patient out-of-pocket costs but could constrain U.S. pricing power and revenue for affected drug manufacturers, warranting portfolio reassessments for investors with pharma exposure.

Analysis

Market structure: The CMS GLOBE (Oct 1, 2025) and GUARD (Jan 1, 2027) pilots shift pricing power toward payers by tying Medicare Part B/D out-of-pocket costs and manufacturer rebates to international benchmarks. Expect concentrated pressure on high-priced biologics and top outpatient drugs (the top 10–20 drugs historically account for a large share of Medicare spend); net price compression of 10–30% on those names is plausible over 12–36 months if benchmarks are enforced. Insurers/managed-care (lower pharmacy spend) and PBMs stand to benefit; incumbent big-pharma with U.S.-heavy pricing will lose margin and free cash flow.

Risk assessment: Tail risks include a successful industry legal challenge delaying implementation into 2027–2028, manufacturers delisting drugs from Medicare, or strategic list‑price increases that negate rebate mechanics. Short-term (next 60–180 days) market moves will hinge on CMS rule details and the first published drug list; medium-term (6–18 months) impacts depend on revenue guidance in FY2026–FY2027 and any supply withdrawals. Hidden dependencies: manufacturers can offset by accelerating launches outside Medicare, shifting to services/assurance contracts, or reclassifying administration channels from Part D to Part B.

Competitive dynamics & cross-asset: Expect accelerated adoption of biosimilars and generic substitution (raising supply elasticity) and a reallocation of R&D/M&A toward non-Medicare markets and specialty indications. Bond markets may price in modest disinflationary effects on healthcare CPI over 2–3 years, marginally tightening real yields; USD and commodities impact should be limited, but biotech equity volatility will rise, increasing option implied vols by 20–40% around earnings/catalysts.

Contrarian view: The market may over-penalize diversified pharma and underweight companies with low Medicare exposure or strong international pricing parity (e.g., firms with >50% ex‑US sales). Small/mid-cap biotech with orphan or pediatric drugs (not broadly used in Medicare) are likely insulated; unintended consequences include narrower formularies and provider bottlenecks if manufacturers pull supply, which could temporarily raise utilization costs elsewhere in the system.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth (UNH) and a 2% long in CVS Health (CVS) with a 6–12 month horizon — thesis: lower Medicare drug outlays reduce pharmacy spend 2–4%, target 8–15% upside; take profits if position appreciates >12% or after CMS final rule publication (within 60 days).
• Trim 3–5% positions in U.S.-centric large-cap pharma: AbbVie (ABBV), Merck (MRK) and Regeneron (REGN); hedge remaining exposure by buying Jan 17, 2026 (≈12-month) puts ~10% OTM sized to cover ~50% of position notional to protect against a 15–30% downside tied to rebate implementation.
• Implement a pair trade: go long UNH (size X) and short ABBV or REGN (size X) for 9–18 months — expects relative outperformance of payers vs high-priced pharma as benchmarks phase in; close or rebalance if CMS excludes >50% of top-spend drugs or if a court injunction delays rollout beyond Q1 2026.
• Monitor CMS publications and the first GLOBE drug list within 30–60 days and company FY2025 guidance over next 90 days; if CMS includes >10 top-spend biologics, increase short pharma allocation by +50% (notional) and add protective puts; if a credible legal injunction is filed within 90 days, reduce shorts to baseline and harvest any realized gains.